$43.79
+9.47%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$39.83
From 52W high+0.00%
Volume12.62M
Market cap$26.93B
P/E (TTM)34.3x
P/S (TTM)6.5x
Div yield—
Key dataOct 23, 2026
Open
$39.83
From 52W high
+0.00%
Volume
12.62M
Market cap
$26.93B
ValuationView details →
P/E (Fwd)
28.1x
EV/EBITDA
25.2x
P/E (TTM)
34.3x
RSI (14)
75.2
MomentumView details →
1D Return
+9.47%
YTD Return
+37.40%
SummaryUpdated Jun 1, 2026
Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. The company went public in 2009 and has established itself as a leading developer of innovative antibody therapeutics for cancer treatment. Genmab has evolved from a research-focused biotech startup into a commercially successful company with multiple approved products and a robust pipeline of experimental treatments. The company operates through strategic partnerships with major pharmaceutical companies while also developing and commercializing its own proprietary medicines.
Similar companies
Latest newsMore news →
GENMAB A/S announced updated follow-up analyses from a Phase 2 study of petosemtamab with FOLFOX or FOLFIRI in metastatic colorectal cancer, reporting objective response rates of 75% in first-line patients, 67% in second-line patients, and 81% among first-line patients with left-sided tumors.11h agoINCYTE CORP and GENMAB A/S announced a clinical trial collaboration in metastatic colorectal cancer.1d ago